Investor Relations

Anchiano urges all holders of its TASE-traded ordinary shares to instruct their banks or brokers to convert their shares to American Depositary Shares (ADSs) at the earliest. Anchiano will pay conversion fees directly to Israeli banks and brokers, and the Bank of New York Mellon will waive its conversion fees, for shareholders who convert on or before May 13, 2019. Contact us with any questions at ADS@anchiano.com

We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need.

Our initial program is the genetic therapy for early stage bladder cancer. Inodiftagene visteplasmid (formerly BC-819), our most advanced investigational agent, is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC).

We are located in Cambridge, MA, and in Jerusalem, and are publicly traded on the Nasdaq and Tel Aviv Stock Exchange (NASDAQ/TASE:ANCN).

Scientific and Medical

Focus on discovering and developing therapies for patients with cancer in areas of unmet need

Initial program: genetic therapy for early stage bladder cancer

Utilizes technology licensed from Hebrew University

Corporate

Founded in 2004; based in Cambridge and Jerusalem

CEO (former Harvard faculty; Ariad chief medical officer) based in Cambridge, building U.S. team and infrastructure

Financial

$39 million (end 2018)
Approximate market capitalization

ADSs, each representing five ordinary shares, publicly traded on Nasdaq (NASDAQ:ANCN)

Ordinary shares, no par value, publicly traded on the TASE (TASE:ANCN)

37.1 million outstanding shares, equivalent to 7.4 million ADSs

50.5 million shares fully diluted, equivalent to 10.1 million ADSs

$7.5 million (end 2018)
cash, no debt

Stock Quote

Nasdaq                                                                    TASE

                    

Intraday delay: 15 minutes

Stock Chart 

Intraday delay: 15 minutes

SEC Company Filings


Filing DateFormDescriptionDownload
4/24/1920-F/A[Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)]PDF
3/25/1920-KAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]PDF
3/14/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
3/12/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
2/21/19SC 13DGeneral statement of acquisition of beneficial ownershipPDF
2/14/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
2/13/19424B4Prospectus [Rule 424(b)(4)]PDF
2/12/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
2/11/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
2/8/198-A12BRegistration of securities [Section 12(b)]PDF
2/8/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
2/7/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
1/30/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
1/7/19F-1Registration statement for certain foreign private issuers PDF
Anchiano Therapeutics Ltd. CIK#: 0001534248 (see all company filings)

Contact Investor Relations

Ashley Robinson, LifeSci Advisors
Email: arr@lifesciadvisors.com

Presentations

Oppenheimer 29th Annual Healthcare Conference 

Click here to view 

 

Corporate Presentation